JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1995; 26:991-994
© 1995 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Sullivan, J.
Right arrow Articles by Wren, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Sullivan, J.
Right arrow Articles by Wren, C

Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants?

JJ O'Sullivan, HM Gardiner, and C Wren

Department of Paediatric Cardiology, Freeman Hospital, Newcastle upon Tyne, England, United Kingdom.

OBJECTIVES. This study compared the safety and efficacy of digoxin and flecainide in the prophylaxis of supraventricular tachycardia in infants. BACKGROUND. Recurrence of supraventricular tachycardia in infants is common. Digoxin is the conventional drug of first choice for prophylaxis, but its efficacy has not been tested in a controlled clinical trial, and there is no consensus on the drug of choice when digoxin is ineffective. METHODS. We reviewed retrospectively the records of all infants with supraventricular tachycardia due to atrioventricular (AV) reentry admitted to our hospital between January 1986 and December 1993. RESULTS. Thirty-nine infants presented with sustained AV reentrant tachycardia at age 1 to 330 days (median 12). Intravenous flecainide was required to maintain immediate control in six patients who were then treated with oral flecainide. The other 33 patients were treated with oral digoxin. There was no recurrence of tachycardia in 14 (42%) of the 33 patients (95% confidence interval [CI] 25% to 61%). In the other 19 patients (58%) (95% CI 39% to 75%), digoxin was replaced by oral flecainide because of multiple recurrence of tachycardia. Full control was achieved in all 19 of these patients (100%) (95% CI 82% to 100%) and in 5 of the 6 patients treated with both intravenous and oral flecainide. Thus, overall, flecainide was effective in 24 (96%) of 25 patients (95% CI 80% to 100%). CONCLUSIONS. Comparison with previous natural history studies suggests that digoxin is ineffective in the prophylaxis of supraventricular tachycardia. Oral flecainide was effective in a small number of infants, with no adverse effects (95% CI 0% to 12%), and may now be preferred as the primary prophylactic agent.


This article has been cited by other articles:


Home page
NeoReviewsHome page
H. R. Singh, S. Garekar, M. L. Epstein, and T. L'Ecuyer
Neonatal Supraventricular Tachycardia (SVT)
NeoReviews, July 1, 2005; 6(7): e339 - e350.
[Full Text] [PDF]


Home page
Arch Pediatr Adolesc MedHome page
S. P. Etheridge and V. E. Judd
Supraventricular Tachycardia in Infancy: Evaluation, Management, and Follow-up
Arch Pediatr Adolesc Med, March 1, 1999; 153(3): 267 - 271.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
C. WREN
Mechanisms of fetal tachycardia
Heart, June 1, 1998; 79(6): 536 - 537.
[Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1995 by the American College of Cardiology Foundation.